Get started
Author

Brigida Stanzione

Treatment of triple negative breast cancer (TNBC): current options and future perspectives
2010 · M. De Laurentiis, D. Cianniello, et al. · Cancer Treatment Reviews · 192
Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications
2016 · Massimiliano Berretta, Carla Cavaliere, et al. · Oncotarget · 80
PDF
Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications
2022 · Alessandro Del Conte, Elisa De Carlo, et al. · International Journal of Molecular Sciences · 76
PDF
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
2016 · Marta Bonotto, Lorenzo Gerratana, et al. · The Breast · 59
PDF
The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
2015 · M Berretta, B Stanzione, et al. · PubMed · 57
Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
2022 · Elisa Bertoli, Elisa De Carlo, et al. · International Journal of Molecular Sciences · 48
PDF
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
2023 · Elisa Bertoli, Elisa De Carlo, et al. · International Journal of Molecular Sciences · 36
PDF
Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies
2025 · Brigida Stanzione, Alessandro Del Conte, et al. · Cancers · 25
PDF
It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature
2018 · Matilde Pensabene, Brigida Stanzione, et al. · BMC Cancer · 23
PDF
Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer
2023 · Brigida Stanzione, Alessandro Del Conte, et al. · International Journal of Molecular Sciences · 22
PDF
EML4-ALK: Update on ALK Inhibitors
2025 · Alessandra Bearz, Elisa Bertoli, et al. · International Journal of Molecular Sciences · 17
PDF
Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
2022 · Elisa De Carlo, Elisa Bertoli, et al. · International Journal of Molecular Sciences · 17
PDF
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
2025 · Lorenzo Foffano, Elisa Bertoli, et al. · International Journal of Molecular Sciences · 14
PDF
The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
2022 · Alessandra Bearz, Elisa De Carlo, et al. · International Journal of Molecular Sciences · 14
PDF
New treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy
2016 · Massimiliano Berretta, Raffaele Di Francia, et al. · Expert Opinion on Pharmacotherapy · 13
Multiple metachronus proliferative fasciitis occurring in different anatomic regions: A case report and review of the literature
2012 · Brigida Stanzione, Immacolata Cozzolino, et al. · Pathology - Research and Practice · 12
Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report
2021 · ELISA DE CARLO, MONICA SCHIAPPACASSI, et al. · In Vivo · 8
PDF
Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer
2025 · Sara Torresan, Martina Bortolot, et al. · International Journal of Molecular Sciences · 7
PDF
Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC
2021 · Elisa De Carlo, Monica Schiappacassi, et al. · Journal of Thoracic Oncology · 7
The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality
2017 · Sebastiano Bordonaro, Massimiliano Berretta, et al. · Current Cancer Drug Targets · 6
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance
2024 · Martina Bortolot, Sara Torresan, et al. · International Journal of Molecular Sciences · 4
PDF
Targeted Therapy in Mesotheliomas: Uphill All the Way
2024 · Elisa Bertoli, Elisa De Carlo, et al. · Cancers · 3
Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC
2024 · Elisa De Carlo, Elisa Bertoli, et al. · Frontiers in Oncology · 3
PDF
Braf-mutant metastatic non–small-cell lung cancer: Real world data from the Italian biomarker atlas database
2025 · Claudio Sini, Alessandro Russo, et al. · European Journal of Cancer · 2
Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer
2013 · Carmine De Angelis, Monica Milano, et al. · Combination Products in Therapy · 2
PDF
Works count: 40
Citation count: 753
H-index: 14
I10-index: 16
Year
Topic
Type